Navigation Links
Drug targets hard-to-reach leukemia stem cells responsible for relapses
Date:1/17/2013

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive and thus vulnerable to a novel cancer stem cell-targeting drug currently under development.

The findings, published in the January 17 online issue of Cell Stem Cell, open the possibility that diseases like chronic myeloid leukemia (CML) and some solid tumor cancers might in combination with other therapies be more effectively treated with this drug, and with a lower chance of relapse.

Led by principal investigator Catriona H. M. Jamieson, MD, PhD, associate professor of medicine and director of stem cell research at UC San Diego Moores Cancer Center, the researchers found that a compound called sabutoclax appears to selectively target LSCs that express particular protein isoforms through alternatively splicing, a fundamental process in which a gene is able to code for multiple proteins.

An emerging class of drugs called tyrosine kinase inhibitors (TKI) such as imitinib (Gleevec), gifitinib (Iressa) and sunitinib (Sutent) has become a popular anti-cancer treatment. However, current TKIs are not 100 percent effective. In cases of CML, for example, some LSCs tucked protectively within bone marrow elude destruction, develop resistance to therapy, self-renew and eventually cause the leukemia to dramatically return.

Jamieson and colleagues found that alternative splicing of BCL2 genes, which code for proteins involved in apoptosis or programmed cell death, specifically promoted malignant transformation of dormant white blood cell precursors into "blast crisis" LSCs. The blast crisis is the final phase of CML when overabundant, abnormal white blood cells crowd out healthy cells, causing serious dysfunction.

Of clinical importance, they noted that sabutoclax, which suppresses all BCL2 anti-apoptotic proteins, renders these marrow-dwelling blast crisis LSCs sensitive and more susceptible to TKI-based therapeutics at doses that do not harm normal progenitor cells.

"Our findings show that pan-BCL2 inhibition will be critical for the eradication of cancer stem cells in CML and that there is an essential link between cancer stem cell dormancy, pro-survival BCL2 isoform expression and therapeutic resistance," Jamieson said. "By using a novel pan-BCL2 inhibitor, we may be able to prevent therapeutic resistance by sensitizing malignant stem cell clones to TKIs."

The findings may have implications for treating solid tumor cancers, such as colon, prostate, breast, and brain cancers, noted Daniel J. Goff, the study's first author.

"With many of these tumor types being shown to harbor cancer stem cells, it raises the question of whether BCL2 family expression as well as isoform-switching may be crucial for the maintenance of cancer stem cells in these diseases as well," he said. "If so, they may also be candidates for treatment with a BCL2 inhibitor like sabutoclax."


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. SMART heart eases heart ache, targets cardiac patients emotional well-being
2. A closer look at PARP-1 reveals potential new drug targets
3. Identity Theft Expert Advises on Why Elders are Targets for Scams and Financial Abuse
4. Gene sequencing project identifies potential drug targets in common childhood brain tumor
5. Celebrex-derived drug targets common childhood bone tumor
6. First-of-its-kind approach nanomedicine design effectively targets cancer with decreased toxicity
7. NIH tools facilitate matching cancer drugs with gene targets
8. Research funding targets bone health
9. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
10. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
11. Study: Vaccine targets malignant brain cancer antigens, significantly lengthens survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug targets hard-to-reach leukemia stem cells responsible for relapses
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/28/2017)... ... 28, 2017 , ... Designers Insurance Agency, a privately owned ... and DC, is announcing a cooperative charity event in conjunction with the Insight ... that lead to memory impairment. , The Insight Memory Care Center (IMCC) offers ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly ... to survey data released today by the American Society for Dermatologic Surgery ... indicates the percentage of consumers considering a cosmetic medical procedure has doubled since ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... solution for many of the health care industry’s hospitals and provider groups, has ... financing portal for select customers. Parasail Health is a San Francisco health-finance startup ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... From June ... The three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... industry, how to connect with today’s savvy consumer, and the latest in hearing ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE: ... Iowa location. The Iowa ... ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. ... pollutants. "Our new cleanroom will ... our Iowa patients," said Phil Rielly ...
(Date:6/5/2017)... June 5, 2017 Kohll,s Pharmacy & Homecare is the ... the United States . The Raizer is a simple ... person up to an almost-standing position within a ... by one assistant and does not require any ... that a child can operate it, and lightweight ...
(Date:6/2/2017)... -- NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company focused ... positive biochemical outcomes related to more frequent hemodialysis with ... be presented at the ERA-EDTA Congress being held June ... The research was conducted by the ... Europe (KIHDNEy) Cohort team with ...
Breaking Medicine Technology: